Helixgate

Helixgate

Uncategorized

Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans

Published

on

More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody. The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s frontrunners.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Merck’s Welireg combo fails in first-line kidney cancer

Published

on

Adding Merck’s Welireg to an existing Keytruda regimen didn’t lead to a significant improvement in newly diagnosed patients with advanced kidney cancer, Merck announced on Tuesday.

The results mark a setback …

Continue Reading

Uncategorized

Merck’s fast-ascending kidney cancer drug hits a setback

Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.

Read More

Published

on

Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.

Read More

Continue Reading

Uncategorized

UnitedHealth breaks down how it plans to spend $1.5B on AI

UnitedHealth breaks down how it plans to spend $1.5B on AI

Published

on

UnitedHealth Group said Tuesday it’s on track to invest $1.5 billion in artificial intelligence this year, both to improve its own operations and provide products to other insurers and healthcare providers.

The healthcare giant is …​ ​Read More

Continue Reading
Advertisement

Trending